Home / GLP-1 Vision Loss Lawyers
Nationwide GLP-1 Vision Loss Attorneys Holding Drug Makers Accountable for Lost Sight
Waking up to a dark patch or a gray blur in one eye is frightening. For a growing number of people across the country who took Ozempic, Wegovy, Mounjaro, and similar medications, that moment marked the start of permanent vision loss. With experience handling defective product cases and taking on powerful defendants, the GLP-1 vision loss lawyers at Drazin & Warshaw, P.C. are helping patients who suffered vision loss hold the drug makers accountable.
Hundreds of lawsuits now allege that manufacturers knew or should have known about a link between these drugs and a serious optic nerve injury, yet failed to warn patients and their doctors. Our team at Drazin & Warshaw, P.C. has recovered more than $500 million for injured clients since our founding in 1947. Our trial attorneys have taken on large corporations in product liability and toxic tort cases, and we now represent people harmed by GLP-1 medications nationwide.
Call 732-333-8141 or fill out our online contact form for a free consultation. You pay no fee unless we recover compensation for you.
Qualifying for a GLP-1 Vision Loss Claim
Every case turns on its own medical facts, but most strong claims share a few features:
- A prescription for a GLP-1 medication
- A diagnosis of NAION or another optic nerve injury from an eye doctor
- Vision loss that began while taking the drug or soon after stopping
- Medical records documenting the timeline
Missing one of these criteria may not rule out a potential claim. During a free review, our GLP-1 vision loss lawyers can examine your pharmacy history and eye care records to judge whether a claim makes sense for you. If it does, we explain which court fits your case, whether that is the federal MDL, the New Jersey litigation, or another state court.
NAION Explained: The Eye Injury Behind Ozempic and GLP-1 Vision Loss Claims
In the ongoing GLP-1 vision loss claims, hundreds of which are currently proceeding, the cause of the injury is a condition called non-arteritic anterior ischemic optic neuropathy (NAION).
NAION occurs when blood flow to the front of the optic nerve suddenly drops. Without enough oxygen, nerve tissue is damaged, and the signals that carry images from your eye to your brain are cut off. Doctors sometimes describe it as a stroke of the optic nerve.
NAION usually strikes one eye without pain or warning. Common signs include:
- Sudden vision loss in one eye, often noticed on waking
- A dark or shadowed area in the upper or lower part of your vision
- Blurred, dim, or washed-out sight
- Colors that appear faded in the affected eye
There is currently no proven treatment that restores vision lost to NAION. Some people also develop the condition in the second eye later. If you notice any of these symptoms, get emergency eye care right away, then tell the treating doctor about every medication you take.
The GLP-1 Medications Named in Vision Loss Lawsuits
GLP-1 receptor agonists mimic a natural hormone that regulates blood sugar and appetite. They are prescribed for type 2 diabetes and chronic weight management. Claims currently involve several brands:
- Ozempic, Wegovy, and Rybelsus: Semaglutide products made by Novo Nordisk
- Mounjaro and Zepbound: Tirzepatide products made by Eli Lilly and Company
- Trulicity: Dulaglutide, also made by Eli Lilly and Company
- Victoza and Saxenda: Liraglutide products made by Novo Nordisk
You do not need to remember the exact brand or dose you used. Pharmacy and insurance records can confirm your prescription history, and our team can request them for you.
The Research Linking GLP-1 Drugs to Vision Loss
Concern about vision loss associated with GLP-1 drugs grew in 2024, when researchers at Massachusetts Eye and Ear published a study in JAMA Ophthalmology that found substantially higher rates of NAION among patients prescribed semaglutide than among patients taking other diabetes or weight loss drugs.
Later studies have reported a smaller but still elevated risk, and research continues.
Regulators outside the United States have acted. In June 2025, the European Medicines Agency recommended listing NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 users. In February 2026, the United Kingdom’s medicines regulator warned doctors of a likely association and advised stopping semaglutide if NAION is confirmed.
U.S. labels for these medications mention vision changes but do not list NAION as a specific risk. That gap sits at the center of the failure-to-warn claims now moving through the courts.
Legal Claims Our GLP-1 Vision Loss Lawyers Pursue for Injured Clients Nationwide
Product liability law varies by state, but claims against drug makers generally rest on three theories:
- Failure to warn: The manufacturer did not adequately disclose the risk of NAION to doctors and patients.
- Design defect: The drug’s risks outweighed its benefits as designed.
- Breach of express warranty: Marketing claims about safety did not match the product’s actual risks.
In many GLP-1 vision loss lawsuits, failure to warn is the core theory. Your attorney must show what the company knew about these risks, when it knew it, and how a clearer warning would have changed your doctor’s decision or your own.
Building that proof takes internal company records, regulatory filings, and testimony from medical witnesses. Our GLP-1 vision loss lawyers are equipped to secure those records, preserve critical evidence, and pursue these claims as far as necessary to secure the compensation our clients are entitled to under the law.
Nationwide GLP-1 Vision Loss Attorneys With Deep New Jersey Roots Handling Individual and Mass Tort Cases Across the Country
New Jersey sits at the heart of this litigation. Novo Nordisk, the maker of Ozempic and Wegovy, runs its U.S. operations from Plainsboro, and the state’s courts host their own coordinated proceeding for NAION claims. As nationwide GLP-1 vision loss attorneys based in that home state, we work within both the New Jersey litigation and the federal MDL just across the river in Philadelphia.
You do not need to live in New Jersey to work with us. We represent clients across the country by phone, video, and secure document sharing, which matters when vision loss makes travel difficult. Clients closer to home can meet us at our offices in Red Bank, Hazlet, Brick, and Westfield.
Compensation Available After Drug-Related Vision Loss
Permanent vision loss reshapes daily life, from reading and driving to working and caring for family. Damages in a successful claim may include:
- Past and future medical bills, including ongoing eye care
- Lost wages and reduced earning capacity
- Vision rehabilitation, adaptive devices, and home modifications
- Transportation costs after losing the ability to drive
- Pain, suffering, and loss of enjoyment of life
The value of each case depends on the severity of the injury, your age, your work, and how the loss affects your independence. We document each category thoroughly so nothing is left out of a demand or verdict.
Steps That Protect Your GLP-1 Vision Loss Claim
The actions you take now give our GLP-1 vision loss lawyers more to work with later:
- Get a full eye examination and keep copies of every test result, including visual field tests and optic nerve imaging.
- Talk with your prescribing doctor before stopping or changing any medication.
- Save pharmacy receipts, prescription labels, and any leftover pens or packaging.
- Write down when your symptoms began and how they have changed.
- Decline to give recorded statements to drug company representatives or insurers.
- Contact an attorney as soon as possible so that you are prepared to take action before filing deadlines approach.
You don’t need to have all the answers before you reach out to legal counsel for a free consultation. We’re ready to meet you where you are and begin examining the facts.
Filing Deadlines for GLP-1 Vision Loss Lawsuits Vary by State
Every state sets its own deadline, called a statute of limitations, for filing a personal injury lawsuit, and some allow as little as one year. In New Jersey, for example, the limit is generally two years under N.J.S.A. 2A:14-2. Many states also apply a discovery rule, which may start the clock only when you knew, or reasonably should have known, that a medication caused your injury.
Many people did not connect their vision loss to a GLP-1 until news of the litigation spread. Because the rules differ so widely from state to state, a prompt review is the safest course.
Why Choose Drazin & Warshaw, P.C. as Your GLP-1 Vision Loss Lawyers
When you’re taking on major pharmaceutical manufacturers in medically complex cases, your choice of legal counsel matters. Here’s what Drazin & Warshaw, P.C. brings to these cases.
Three Generations and More Than $500 Million Recovered
Louis M. Drazin founded our firm in 1947, and his family carries that work forward today. Over more than 75 years, we have recovered over $500 million in verdicts and settlements for clients, and we prepare every case as though it will go to trial.
Three Certified Civil Trial Attorneys
Three of our attorneys, Dennis A. Drazin, Brian D. Drazin, and Christopher R. Brown, are certified by the Supreme Court of New Jersey as Civil Trial Attorneys. This credential is held by only a small fraction of the state’s lawyers. That trial depth matters when a case turns on complex medical evidence presented to a jury.
Proven Against Billion-Dollar Corporations
Attorney Justin Drazin has drawn national attention for litigating against multi-billion dollar corporations, and several of our product liability and toxic tort verdicts have been published in the New Jersey Law Journal and VerdictSearch. As nationwide GLP-1 vision loss attorneys, we bring that same readiness to cases against drug manufacturers like Novo Nordisk and Eli Lilly.
No Fee Unless We Win
We handle vision loss cases on a contingency basis, so you owe no attorney fees unless we recover compensation. That arrangement lets you pursue a claim against a major manufacturer without paying out of pocket for legal representation.
Contact the Nationwide GLP-1 Vision Loss Attorneys at Drazin & Warshaw Today for Your Free Consultation
For claimants who lost their sight after taking a medication they trusted to support diabetes treatment or weight loss efforts, this consequence is so much more than a simple side effect. It’s a life-changing type of harm, and you should not have to absorb it and the full range of costs that accompany it alone.
Whether you are ready to file a lawsuit or simply want to know your options, our GLP-1 vision loss lawyers can review your records at no cost. Call 732-333-8141 or fill out our online contact form to speak with our GLP-1 vision loss attorneys from anywhere in the country.
GLP-1 Vision Loss Lawsuit Updates for 2026
Vision loss cases now proceed on two coordinated tracks, one federal and one in New Jersey state court.
On December 15, 2025, the Judicial Panel on Multidistrict Litigation created MDL No. 3163 in the U.S. District Court for the Eastern District of Pennsylvania. Judge Karen S. Marston presides, and she also oversees the separate MDL for GLP-1 gastrointestinal injuries. The court held a Science Day on June 2, 2026, where both sides presented medical evidence on NAION. As of September 1, 2026, the MDL held 216 pending cases.
In late 2025, the Supreme Court of New Jersey designated NAION claims as their own multicounty litigation, separate from gastrointestinal claims, and assigned both to Bergen County Superior Court Judge Gregg A. Padovano. Both tracks are in pretrial discovery, and no global settlement has been announced.
The litigation drew national attention in September 2026, when NBC Nightly News reported on the hundreds of patients suing Novo Nordisk and Eli Lilly. Both companies dispute the claims, and Novo Nordisk has said it is vigorously defending the lawsuits. New cases continue to be filed, and our attorneys are ready to assist the injured, starting with a free consultation.
Frequently Asked Questions About GLP-1 Vision Loss Lawsuits
Can Ozempic cause blindness? Research has linked semaglutide, the active ingredient in Ozempic and Wegovy, to a higher risk of NAION, an optic nerve injury that can cause sudden, permanent vision loss in one eye. European regulators now list NAION as a very rare side effect. Lawsuits allege the manufacturer failed to warn U.S. patients of this risk. Causation is still being litigated, and each case depends on its medical facts.
Can I file a claim if I took Mounjaro or Zepbound instead of Ozempic? Possibly. Vision-loss claims have been asserted involving multiple GLP-1 medications, and the federal NAION litigation includes claims against both Novo Nordisk and Eli Lilly. We review which drug you took, how long you took it, and when your symptoms began to evaluate whether you may have a claim.
Do I need a NAION diagnosis to file a lawsuit? A documented diagnosis from an ophthalmologist or neuro-ophthalmologist makes a claim much stronger, because it establishes the specific injury alleged in the litigation. If you lost vision but never received a clear diagnosis, we can help you gather your records and arrange an evaluation. Other optic nerve or retinal injuries may also be worth reviewing, depending on the specific facts of your situation.
Is this litigation a class action? No. The federal MDL and the New Jersey multicounty litigation group individual lawsuits for shared pretrial steps like discovery and medical testimony. Unlike a class action, each plaintiff keeps an individual case, and any compensation reflects that person’s own injuries and losses. This structure allows your damages to be evaluated on their own merits.
How much does it cost to hire Drazin & Warshaw, P.C. for a GLP-1 vision loss case? Nothing up front. We represent vision loss clients on a contingency fee basis, which means our fee comes from a portion of any settlement or verdict we obtain. If we do not recover compensation for you, you owe no attorney fees. Your initial consultation is free and carries no obligation.
